Nothing said here yet.
to join the conversation.
| Kaye MarkEVP & CFO | Sell | 2,343 | $1.0M | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 1,720 | $757.6K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 1,660 | $724.1K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 1,160 | $509.5K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 827 | $368.9K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 560 | $244.8K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 480 | $212.5K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 440 | $195.3K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 400 | $173.6K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 321 | $139.7K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 273 | $122.1K | Thu, Oct 22 |
| Kaye MarkEVP & CFO | Sell | 240 | $105.2K | Thu, Oct 22 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is MOH a good stock to buy? We came across a bullish thesis on Molina Healthcare, Inc. on Valueinvestorsclub.com by banjo1055.
Investors need to pay close attention to ELV stock based on the movements in the options market lately.
Elevance Health just posted its Q3 2026 scorecard and the stock has shrugged off any hesitation.
Health insurance provider Elevance Health (NYSE:ELV) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $50.44 billion. Its non-GAAP profit of $6.99 per share was 48.9% above analysts’ consensus estimates.
Clinical efficiency gains and integrated pharmacy benefits are lengthening the runway for margin expansion beyond 2026.
Elevance Health (NYSE:ELV) has appointed Jeff Park as President of Carelon, its services-focused subsidiary. Park joins Elevance Health with a background in healthcare, pharmacy, and technology businesses, reflecting a services-focused leadership pick.
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CEO Boudreaux raised full-year guidance on Medicaid improvements and Carelon momentum.
Moby summary of Elevance Health Inc.'s Q3 2026 earnings call